TG THERAPEUTICS INC (TGTX) Stock Fundamental Analysis

NASDAQ:TGTX • US88322Q1085

29.53 USD
+0.07 (+0.24%)
At close: Feb 20, 2026
29.4 USD
-0.13 (-0.44%)
After Hours: 2/20/2026, 8:07:17 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

5

We assign a fundamental rating of 5 out of 10 to TGTX. TGTX was compared to 521 industry peers in the Biotechnology industry. Both the profitability and the financial health of TGTX get a neutral evaluation. Nothing too spectacular is happening here. TGTX is not priced too expensively while it is growing strongly. Keep and eye on this one!


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • TGTX had positive earnings in the past year.
  • TGTX had a negative operating cash flow in the past year.
  • In multiple years TGTX reported negative net income over the last 5 years.
  • In the past 5 years TGTX always reported negative operating cash flow.
TGTX Yearly Net Income VS EBIT VS OCF VS FCFTGTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100M -200M -300M

1.2 Ratios

  • With an excellent Return On Assets value of 43.65%, TGTX belongs to the best of the industry, outperforming 99.23% of the companies in the same industry.
  • With an excellent Return On Equity value of 73.69%, TGTX belongs to the best of the industry, outperforming 99.04% of the companies in the same industry.
  • The Return On Invested Capital of TGTX (9.35%) is better than 94.24% of its industry peers.
Industry RankSector Rank
ROA 43.65%
ROE 73.69%
ROIC 9.35%
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
TGTX Yearly ROA, ROE, ROICTGTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600

1.3 Margins

  • With an excellent Profit Margin value of 84.13%, TGTX belongs to the best of the industry, outperforming 98.66% of the companies in the same industry.
  • TGTX has a Operating Margin of 19.32%. This is amongst the best in the industry. TGTX outperforms 94.24% of its industry peers.
  • TGTX's Gross Margin of 85.34% is amongst the best of the industry. TGTX outperforms 87.91% of its industry peers.
  • TGTX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.32%
PM (TTM) 84.13%
GM 85.34%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
TGTX Yearly Profit, Operating, Gross MarginsTGTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -50K -100K -150K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. Health

2.1 Basic Checks

  • TGTX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • TGTX has more shares outstanding than it did 1 year ago.
  • TGTX has more shares outstanding than it did 5 years ago.
  • TGTX has a worse debt/assets ratio than last year.
TGTX Yearly Shares OutstandingTGTX Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M
TGTX Yearly Total Debt VS Total AssetsTGTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 6.59 indicates that TGTX is not in any danger for bankruptcy at the moment.
  • TGTX's Altman-Z score of 6.59 is fine compared to the rest of the industry. TGTX outperforms 75.82% of its industry peers.
  • TGTX has a Debt/Equity ratio of 0.40. This is a healthy value indicating a solid balance between debt and equity.
  • TGTX's Debt to Equity ratio of 0.40 is on the low side compared to the rest of the industry. TGTX is outperformed by 69.10% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Altman-Z 6.59
ROIC/WACC1.07
WACC8.71%
TGTX Yearly LT Debt VS Equity VS FCFTGTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M 400M

2.3 Liquidity

  • TGTX has a Current Ratio of 3.82. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
  • TGTX has a Current ratio of 3.82. This is comparable to the rest of the industry: TGTX outperforms 45.87% of its industry peers.
  • TGTX has a Quick Ratio of 2.89. This indicates that TGTX is financially healthy and has no problem in meeting its short term obligations.
  • TGTX's Quick ratio of 2.89 is on the low side compared to the rest of the industry. TGTX is outperformed by 62.96% of its industry peers.
Industry RankSector Rank
Current Ratio 3.82
Quick Ratio 2.89
TGTX Yearly Current Assets VS Current LiabilitesTGTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

8

3. Growth

3.1 Past

  • TGTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 563.64%, which is quite impressive.
  • TGTX shows a strong growth in Revenue. In the last year, the Revenue has grown by 100.88%.
  • TGTX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 364.59% yearly.
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%

3.2 Future

  • The Earnings Per Share is expected to grow by 92.84% on average over the next years. This is a very strong growth
  • TGTX is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 40.46% yearly.
EPS Next Y2065.68%
EPS Next 2Y240.49%
EPS Next 3Y160.33%
EPS Next 5Y92.84%
Revenue Next Year91.84%
Revenue Next 2Y67.59%
Revenue Next 3Y55.28%
Revenue Next 5Y40.46%

3.3 Evolution

  • Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
TGTX Yearly Revenue VS EstimatesTGTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 500M 1B 1.5B 2B 2.5B
TGTX Yearly EPS VS EstimatesTGTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 2 -2 4

More info and screens

Find the best growth stocksShow best growing peers

5

4. Valuation

4.1 Price/Earnings Ratio

  • TGTX is valuated quite expensively with a Price/Earnings ratio of 57.90.
  • Based on the Price/Earnings ratio, TGTX is valued cheaply inside the industry as 90.79% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 26.99. TGTX is valued rather expensively when compared to this.
  • TGTX is valuated rather expensively with a Price/Forward Earnings ratio of 18.19.
  • Compared to the rest of the industry, the Price/Forward Earnings ratio of TGTX indicates a rather cheap valuation: TGTX is cheaper than 93.86% of the companies listed in the same industry.
  • When comparing the Price/Forward Earnings ratio of TGTX to the average of the S&P500 Index (28.02), we can say TGTX is valued slightly cheaper.
Industry RankSector Rank
PE 57.9
Fwd PE 18.19
TGTX Price Earnings VS Forward Price EarningsTGTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

  • Based on the Enterprise Value to EBITDA ratio, TGTX is valued cheaper than 91.55% of the companies in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 46.14
TGTX Per share dataTGTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • The decent profitability rating of TGTX may justify a higher PE ratio.
  • TGTX's earnings are expected to grow with 160.33% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.03
PEG (5Y)N/A
EPS Next 2Y240.49%
EPS Next 3Y160.33%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • TGTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

TG THERAPEUTICS INC

NASDAQ:TGTX (2/20/2026, 8:07:17 PM)

After market: 29.4 -0.13 (-0.44%)

29.53

+0.07 (+0.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-03
Earnings (Next)03-03
Inst Owners63.66%
Inst Owner Change1.6%
Ins Owners6.78%
Ins Owner Change-20.54%
Market Cap4.69B
Revenue(TTM)531.90M
Net Income(TTM)447.47M
Analysts78.67
Price Target45.05 (52.56%)
Short Float %19.65%
Short Ratio15.48
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-25.98%
Min EPS beat(2)-28.7%
Max EPS beat(2)-23.26%
EPS beat(4)1
Avg EPS beat(4)-14.65%
Min EPS beat(4)-83.83%
Max EPS beat(4)77.18%
EPS beat(8)3
Avg EPS beat(8)0.93%
EPS beat(12)5
Avg EPS beat(12)39.18%
EPS beat(16)8
Avg EPS beat(16)34.08%
Revenue beat(2)1
Avg Revenue beat(2)-0.96%
Min Revenue beat(2)-6.11%
Max Revenue beat(2)4.19%
Revenue beat(4)3
Avg Revenue beat(4)1.06%
Min Revenue beat(4)-6.11%
Max Revenue beat(4)6.12%
Revenue beat(8)7
Avg Revenue beat(8)4.47%
Revenue beat(12)9
Avg Revenue beat(12)25.49%
Revenue beat(16)11
Avg Revenue beat(16)25.09%
PT rev (1m)-0.91%
PT rev (3m)2.32%
EPS NQ rev (1m)-1.75%
EPS NQ rev (3m)33.81%
EPS NY rev (1m)-0.11%
EPS NY rev (3m)293.06%
Revenue NQ rev (1m)2.92%
Revenue NQ rev (3m)5.41%
Revenue NY rev (1m)0.65%
Revenue NY rev (3m)4.47%
Valuation
Industry RankSector Rank
PE 57.9
Fwd PE 18.19
P/S 8.81
P/FCF N/A
P/OCF N/A
P/B 7.72
P/tB 7.72
EV/EBITDA 46.14
EPS(TTM)0.51
EY1.73%
EPS(NY)1.62
Fwd EY5.5%
FCF(TTM)-0.44
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS3.35
BVpS3.82
TBVpS3.82
PEG (NY)0.03
PEG (5Y)N/A
Graham Number6.62
Profitability
Industry RankSector Rank
ROA 43.65%
ROE 73.69%
ROCE 11.84%
ROIC 9.35%
ROICexc 11.02%
ROICexgc 11.02%
OM 19.32%
PM (TTM) 84.13%
GM 85.34%
FCFM N/A
ROA(3y)-35.91%
ROA(5y)-48.82%
ROE(3y)-121.2%
ROE(5y)-112.84%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.04%
GM growth 5YN/A
F-Score5
Asset Turnover0.52
Health
Industry RankSector Rank
Debt/Equity 0.4
Debt/FCF N/A
Debt/EBITDA 2.39
Cap/Depr 357.45%
Cap/Sales 0.03%
Interest Coverage 4.15
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.82
Quick Ratio 2.89
Altman-Z 6.59
F-Score5
WACC8.71%
ROIC/WACC1.07
Cap/Depr(3y)23.6%
Cap/Depr(5y)87.79%
Cap/Sales(3y)0.17%
Cap/Sales(5y)48.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)563.64%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%700%
EPS Next Y2065.68%
EPS Next 2Y240.49%
EPS Next 3Y160.33%
EPS Next 5Y92.84%
Revenue 1Y (TTM)100.88%
Revenue growth 3Y266.39%
Revenue growth 5Y364.59%
Sales Q2Q%92.79%
Revenue Next Year91.84%
Revenue Next 2Y67.59%
Revenue Next 3Y55.28%
Revenue Next 5Y40.46%
EBIT growth 1Y20452.3%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year398.51%
EBIT Next 3Y148.95%
EBIT Next 5YN/A
FCF growth 1Y-66.94%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.55%
OCF growth 3YN/A
OCF growth 5YN/A

TG THERAPEUTICS INC / TGTX FAQ

What is the fundamental rating for TGTX stock?

ChartMill assigns a fundamental rating of 5 / 10 to TGTX.


What is the valuation status for TGTX stock?

ChartMill assigns a valuation rating of 5 / 10 to TG THERAPEUTICS INC (TGTX). This can be considered as Fairly Valued.


Can you provide the profitability details for TG THERAPEUTICS INC?

TG THERAPEUTICS INC (TGTX) has a profitability rating of 6 / 10.


Can you provide the financial health for TGTX stock?

The financial health rating of TG THERAPEUTICS INC (TGTX) is 4 / 10.


What is the earnings growth outlook for TG THERAPEUTICS INC?

The Earnings per Share (EPS) of TG THERAPEUTICS INC (TGTX) is expected to grow by 2065.68% in the next year.